| Literature DB >> 26761524 |
Jinfeng Zhou1,2, Jianjun Yang1, Xing Fan3, Sijun Hu1, Fenli Zhou1, Jiaqiang Dong1, Song Zhang1, Yulong Shang1, Xiaoming Jiang4, Hao Guo1, Ning Chen1, Xiao Xiao1, Jianqiu Sheng5, Kaichun Wu1, Yongzhan Nie1, Daiming Fan1.
Abstract
LAMP2A is the key protein of chaperone-mediated autophagy (CMA), downregulation of LAMP2A leads to CMA blockade. CMA activation has been implicated in cancer growth, but the exact mechanisms are unclear. Elevated expression of LAMP2A was found in 8 kinds of tumors (n=747), suggesting that LAMP2A may have an important role in cancer progression. Unsurprisingly, LAMP2A knockdown in gastric cancer (GC) cells hindered proliferation, accompanied with altered expression of cell cycle-related proteins and accumulation of RND3/RhoE. Interactomic and KEGG analysis revealed that RND3 was a putative CMA substrate. Further study demonstrated that RND3 silencing could partly rescue the proliferation arrest induced by LAMP2A knockdown; RND3 was increased upon lysosome inhibition via both chemicals and LAMP2A-shRNA; Furthermore, RND3 could interact with CMA components HSPA8 and LAMP2A, and be engulfed by isolated lysosomes. Thus, constant degradation of RND3 by CMA is required to sustain rapid proliferation of GC cells. At last, the clinical significance of LAMP2A was explored in 593 gastric noncancerous lesions and 173 GC tissues, the results revealed that LAMP2A is a promising biomarker for GC early warning and prognosis of female GC patients.Entities:
Keywords: CMA; LAMP2A; RND3; gastric cancer; proliferation
Mesh:
Substances:
Year: 2016 PMID: 26761524 PMCID: PMC4836009 DOI: 10.1080/15548627.2015.1136770
Source DB: PubMed Journal: Autophagy ISSN: 1554-8627 Impact factor: 16.016